We then compared the ability of CRB‐2131 to protect 5XFAD mice (3.5‐month‐old) from cognitive damage to donepezil, which is a conventional cholinesterase inhibitor therapy for AD.[33] CRB‐2131 at 10 mpk protected the cognition of the 5XFAD mice better than 10 μg kg−1 donepezil given in the same regimen (q.d., P.O., and 10 weeks), as shown by the NOR, Y‐maze, and MWM tests (Figure S10, Supporting Information). The gene discussed is BCHE; the disease is Alzheimer disease.